<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485406</url>
  </required_header>
  <id_info>
    <org_study_id>115373</org_study_id>
    <nct_id>NCT01485406</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers</brief_title>
  <official_title>Safety and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine 2830930A When Administered as a Single Dose in Healthy Toddlers Aged 12-23 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the
      GSK Biologicals' pneumococcal vaccine 2830930A in toddlers aged 12 to 23 months at study
      entry.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2011</start_date>
  <completion_date type="Actual">March 15, 2012</completion_date>
  <primary_completion_date type="Actual">March 15, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of each grade 3 solicited adverse event with relationship to vaccination</measure>
    <time_frame>Within 7 days (Day 0-Day 6) after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of grade 3 unsolicited adverse events with relationship to vaccination</measure>
    <time_frame>Within 31 days (Day 0-Day 30) after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events with relationship to vaccination</measure>
    <time_frame>During the entire study (from Month 0 up to Month 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of each solicited adverse event</measure>
    <time_frame>Within 7 days (Day 0-Day 6) after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of each unsolicited adverse event</measure>
    <time_frame>Within 31 days (Day 0-Day 30) after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse event</measure>
    <time_frame>During the entire study (from Month 0 up to Month 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the immune responses to the components of the 2830930A vaccine</measure>
    <time_frame>One month post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Pn Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddlers 12-23 months of age receiving GSK2830930A vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Toddlers 12-23 months of age receiving Synflorix.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK2830930A</intervention_name>
    <description>1 dose administered intramuscularly</description>
    <arm_group_label>Pn Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorixâ„¢</intervention_name>
    <description>1 dose administered intramuscularly</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable
             Representative(s) (LARs) can and will comply with the requirements of the protocol.

          -  A male or female between, and including 12 to 23 months of age at the time of
             vaccination.

          -  Written informed consent obtained from the parents/LAR(s) of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Born after a gestation period of at least 36 weeks.

          -  Previously completed three-dose vaccination course with Synflorix.

        Exclusion Criteria:

          -  Child in care.

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth.

          -  Planned administration/administration of a vaccine containing diphtheria- or tetanus-
             toxoid or CRM197 and not foreseen by the study protocol during any time of the study
             period, or of any other vaccines not foreseen by the protocol in the period starting
             from 30 days before the vaccine dose and ending 30 days after, with the exception of
             licensed influenza vaccines.

               -  The licensed influenza vaccines are always allowed, even if concomitantly
                  administered with the study vaccines but should be documented in the &quot;Concomitant
                  vaccination&quot; of the electronic Case Report Form.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  Family history of congenital or hereditary immunodeficiency.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine(s).

          -  Major congenital defects or serious chronic illness, including Kawasaki's syndrome.

          -  History of any neurological disorders or seizures, including conditions such as
             hypotensive-hyporesponsive episodes, encephalopathy and any convulsions (afebrile and
             febrile).

          -  Acute disease and/or fever at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding vaccination or planned administration during study period.

          -  Any medical condition which might interfere with the assessment of the study
             objectives in the opinion of the investigator.

          -  Previous receipt of a booster dose (fourth dose) of Synflorix.

          -  Anaphylaxis following previous administration of vaccines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berchtesgaden</city>
        <state>Bayern</state>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bindlach</city>
        <state>Bayern</state>
        <zip>95463</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braunatal</city>
        <state>Hessen</state>
        <zip>34225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-Pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/115373?search=study&amp;b%22b''%22#rs</url>
    <description>Results for study 115373 can be found on the GSK Clinical Study Register</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilus influenzae</keyword>
  <keyword>Safety</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Toddlers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

